Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Market Analysis & Valuation

UpdatedJan 11, 2026
DataAggregated Company Financials
Companies134
  • 7D6.8%
  • 3M7.6%
  • 1Y-18.5%
  • YTD6.8%

Over the last 7 days, the market has risen 6.8%, driven by gains of 13% in the Healthcare sector. Longer term the market is actually down 19% over the past year. As for the next few years, earnings are expected to grow by 5.9% per annum.

Trending IndustriesBiotech

Market Valuation and Performance

Has the Danish Market valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 11 Jan 2026DKK 4.5tDKK 2.0tDKK 261.1b16.5x17.1x2.3x
Tue, 09 Dec 2025DKK 4.0tDKK 2.0tDKK 261.0b14.4x15.3x2x
Thu, 06 Nov 2025DKK 3.9tDKK 2.0tDKK 286.4b14.7x13.6x2x
Sat, 04 Oct 2025DKK 4.1tDKK 1.9tDKK 287.3b15.1x14.2x2.1x
Mon, 01 Sep 2025DKK 4.0tDKK 1.9tDKK 287.0b15x14x2.1x
Wed, 30 Jul 2025DKK 4.0tDKK 1.9tDKK 262.4b15.7x15.4x2.2x
Fri, 27 Jun 2025DKK 4.3tDKK 1.9tDKK 261.9b15.5x16.5x2.3x
Sun, 25 May 2025DKK 4.4tDKK 1.9tDKK 264.0b15.5x16.7x2.4x
Tue, 22 Apr 2025DKK 4.2tDKK 1.9tDKK 258.2b13.8x16.1x2.2x
Thu, 20 Mar 2025DKK 5.0tDKK 1.9tDKK 260.3b15.9x19.1x2.7x
Sat, 15 Feb 2025DKK 5.0tDKK 1.9tDKK 263.4b13.7x19x2.7x
Mon, 13 Jan 2025DKK 5.3tDKK 1.8tDKK 237.5b13.8x22.3x2.9x
Wed, 11 Dec 2024DKK 6.0tDKK 1.8tDKK 237.8b14.2x25.3x3.3x
Fri, 08 Nov 2024DKK 5.8tDKK 1.8tDKK 235.8b14.4x24.5x3.2x
Sun, 06 Oct 2024DKK 6.0tDKK 1.7tDKK 180.2b15.7x33.3x3.4x
Tue, 03 Sep 2024DKK 6.7tDKK 1.7tDKK 180.2b15.4x37.2x3.9x
Thu, 01 Aug 2024DKK 6.7tDKK 1.7tDKK 185.6b15.5x35.9x3.9x
Sat, 29 Jun 2024DKK 7.0tDKK 1.7tDKK 184.8b15.8x37.8x4.1x
Mon, 27 May 2024DKK 6.7tDKK 1.7tDKK 184.6b15.4x36.2x3.9x
Wed, 24 Apr 2024DKK 6.5tDKK 1.7tDKK 192.7b15.1x33.5x3.8x
Fri, 22 Mar 2024DKK 6.5tDKK 1.7tDKK 192.1b14.4x33.8x3.8x
Sun, 18 Feb 2024DKK 6.3tDKK 1.7tDKK 190.3b13.8x33.1x3.7x
Tue, 16 Jan 2024DKK 5.7tDKK 1.8tDKK 216.6b13.5x26.5x3.2x
Thu, 14 Dec 2023DKK 5.3tDKK 1.8tDKK 217.5b13.3x24.4x3x
Sat, 11 Nov 2023DKK 5.3tDKK 1.8tDKK 218.1b12.5x24.2x3x
Mon, 09 Oct 2023DKK 5.2tDKK 1.9tDKK 284.5b13.1x18.4x2.8x
Wed, 06 Sep 2023DKK 5.4tDKK 1.9tDKK 284.6b13.3x18.9x2.9x
Fri, 04 Aug 2023DKK 5.0tDKK 1.9tDKK 323.5b13.4x15.3x2.6x
Sun, 02 Jul 2023DKK 5.1tDKK 1.9tDKK 322.2b13.8x15.8x2.6x
Tue, 30 May 2023DKK 5.2tDKK 1.9tDKK 325.2b14.4x16x2.7x
Thu, 27 Apr 2023DKK 5.0tDKK 1.9tDKK 342.6b15x14.5x2.6x
Sat, 25 Mar 2023DKK 4.8tDKK 1.9tDKK 346.9b13.5x13.9x2.5x
Mon, 20 Feb 2023DKK 4.8tDKK 1.9tDKK 347.0b14.2x13.8x2.5x
Wed, 18 Jan 2023DKK 4.7tDKK 1.9tDKK 356.5b13.7x13.1x2.4x
Price to Earnings Ratio

13.1x


Total Market Cap: DKK 4.7tTotal Earnings: DKK 356.5bTotal Revenue: DKK 1.9tTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Market Price to Earnings3Y Average 22.2x202420252026
Current Market PE
  • Investors are pessimistic on the Danish market, indicating that they anticipate earnings will not grow as fast as they have historically.
  • The market is trading at a PE ratio of 17.1x which is lower than its 3-year average PE of 22.2x.
Past Earnings Growth
  • The earnings for Danish listed companies have declined 9.9% per year over the last three years.
  • Meanwhile revenues have been flat.
  • This means that either the cost of doing business or the level of investment back into businesses is increasing since sales have remained steady while profits have fallen.

Sector Trends

Which sectors have driven the changes within the Danish Market?

DK Market6.83%
Energy15.65%
Healthcare12.72%
Materials6.22%
Industrials3.29%
Consumer Staples2.07%
Utilities1.91%
Real Estate1.88%
Telecom1.69%
Tech1.32%
Financials-1.79%
Consumer Discretionary-10.10%
Sector PE
  • Investors favour the Tech sector the most for future growth, which is trading above its 3-year average PE ratio of 52.1x.
    • The market's confidence is likely because analysts are expecting annual earnings growth of 56.7% which is higher than its past year's earnings decline of 17.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Tech sector, expecting annual earnings growth of 57% over the next 5 years.
  • This is better than its past earnings decline of 17% per year.
  • In contrast, the Energy sector is expected to see its earnings decline by 35% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuationSector
NOVO B Novo NordiskDKK 381.4515.5%
+DKK 227.5b		-39.7%PE16.3xHealthcare
DSV DSVDKK 1.68k5.1%
+DKK 19.2b		11.0%PE41.9xIndustrials
NSIS B NovozymesDKK 421.806.3%
+DKK 11.6b		4.7%PE48xMaterials
GMAB GenmabDKK 2.18k8.7%
+DKK 10.8b		35.7%PE13.2xHealthcare
COLO B ColoplastDKK 566.005.5%
+DKK 6.7b		-29.0%PE35.1xHealthcare
See more

Market Insights

Header cover image
Which Markets Will Sink or Swim in 2026? 🌍
Richard Bowman avatar
Richard Bowman
|
|
What research teams agree on – and where they don’t – heading into 2026.
Continue reading
Three Sectors Expected to Rally in 2026 📈
Last Week

Three Sectors Expected to Rally in 2026 📈

Latest News

PNDORA
DKK 588.40
Pandora
7D
-15.4%
1Y
-55.8%
COLO B
DKK 566.00
Coloplast
7D
5.5%
1Y
-29.0%

COLO B: Sustained Margins And Dividend Payouts Will Support Future Upside

Narrative update The analyst price target for Coloplast has edged up by about DKK 0.30 to reflect slightly higher fair value estimates. Recent Street research shows a mix of views, with some analysts lifting targets toward DKK 535 and others resetting them closer to DKK 640, which has led to modest adjustments to discount rate, revenue growth, profit margin, and future P/E assumptions.
MATAS
DKK 107.80
Matas
7D
-12.9%
1Y
-22.0%
NOVO B
DKK 381.45
Novo Nordisk
7D
15.5%
1Y
-39.7%

NOVO B: Future Returns Will Rely On Oral Obesity Treatment And Legal Risks

Narrative Update Analysts have nudged their fair value estimate for Novo Nordisk slightly lower, from $393.04 to $392.29, as small adjustments to revenue growth, profit margin, and future P/E assumptions result in a marginally reduced price target. Analyst Commentary Recent tweaks to fair value for Novo Nordisk reflect relatively modest shifts in assumptions rather than a major change in the overall thesis.
KBHL
DKK 6,640.00
Københavns Lufthavne
7D
-2.9%
1Y
5.4%
DANSKE
DKK 313.70
Danske Bank
7D
-1.8%
1Y
50.2%

DANSKE: Future Returns Will Reflect Earnings Durability And Easing Legal Overhang

Analysts have nudged their fair value estimate for Danske Bank up from DKK 308 to DKK 310, reflecting a series of recent price target increases (including moves to DKK 295 and DKK 319) and small adjustments in discount rate, profit margin and forward P/E assumptions. Analyst Commentary Recent research on Danske Bank has centered on a cluster of price target revisions, with several large firms updating their views within a short period.
VWS
DKK 183.15
Vestas Wind Systems
7D
2.5%
1Y
95.9%

VWS: Future Execution Risks May Undermine Raised Outlook And Earnings Guidance

Analysts lifted their price target on Vestas Wind Systems to DKK 173 from DKK 164, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E that support a slightly higher long term outlook for the shares. Analyst Commentary Bullish Takeaways Bullish analysts frame the new DKK 173 target as reflecting updated views on fair value that they see as better aligned with the company’s longer term earnings potential.
GMAB
DKK 2,182.00
Genmab
7D
8.7%
1Y
35.7%

GMAB: Late Stage Oncology Focus Will Drive Stronger Margins And Repricing

Analysts have increased their fair value estimate for Genmab from DKK 2,700 to approximately DKK 3,060, reflecting updated assumptions that combine lower projected revenue growth with higher profit margins and a reduced future P/E multiple. What's in the News Genmab plans to discontinue further clinical development of acasunlimab and to concentrate resources on late stage programs such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan, described as part of its disciplined portfolio and capital allocation framework (Key Developments).
ZEAL
DKK 419.90
Zealand Pharma
7D
-8.7%
1Y
-42.9%

Zealand Pharma A/S' (CPH:ZEAL) Share Price Is Matching Sentiment Around Its Revenues

Jan 03
Zealand Pharma A/S' (CPH:ZEAL) Share Price Is Matching Sentiment Around Its Revenues
MAERSK B
DKK 15,105.00
A.P. Møller - Mærsk
7D
2.8%
1Y
37.8%

MAERSK B: Freight Cycle Uncertainty Will Meet Improving Margin And Cash Flow Outlook

The analyst price target for A.P. Møller, Mærsk has been modestly revised higher, supported by analysts highlighting improving revenue growth and profit margin expectations despite mixed target moves between roughly DKK 8,800 and DKK 14,352. Analyst Commentary Recent Street research on A.P. Møller, Mærsk reflects a widening dispersion in valuation views, with downside risk flagged by JPMorgan at DKK 8,800 while more constructive forecasts extend up to DKK 14,352.
DSV
DKK 1,681.50
DSV
7D
5.1%
1Y
11.0%

DSV Margin Discipline Will Support Upside Despite Slight Price Objective Cut

Analysts have trimmed their price target on DSV slightly, to DKK 1,915 from DKK 1,925. This reflects marginally slower expected revenue growth, offset by a modest improvement in profit margins and valuation multiples.
ALSYDB
DKK 545.00
AL Sydbank
7D
-4.5%
1Y
47.6%

Industry Analysts Just Made A Stunning Upgrade To Their AL Sydbank A/S (CPH:ALSYDB) Revenue Forecasts

Dec 14
Industry Analysts Just Made A Stunning Upgrade To Their AL Sydbank A/S (CPH:ALSYDB) Revenue Forecasts
TRYG
DKK 159.20
Tryg
7D
-3.6%
1Y
5.2%
ALMB
DKK 18.06
Alm. Brand
7D
-2.9%
1Y
29.1%

Alm. Brand A/S (CPH:ALMB) Not Flying Under The Radar

Dec 03
Alm. Brand A/S (CPH:ALMB) Not Flying Under The Radar
ORSTED
DKK 130.45
Ørsted
7D
1.9%
1Y
-56.2%
NSIS B
DKK 421.80
Novozymes
7D
6.3%
1Y
4.7%